Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
SHERWIN WILLIAMS CO | Director | Common Stock | 12.4K | $4.19M | $338.25 | Apr 4, 2025 | Direct |
REGENERON PHARMACEUTICALS, INC. | Director | Common Stock | 2.35K | $1.67M | $708.19 | Jan 2, 2025 | Direct |
PRUDENTIAL FINANCIAL INC | Director | Common Stock | 11.6K | $1.37M | $117.95 | May 9, 2024 | Direct |
PRUDENTIAL FINANCIAL INC | Director | Notional Shares - Mandatory | 12.8K | $1.35M | $105.04 | Mar 13, 2025 | Direct |
SHERWIN WILLIAMS CO | Director | Common Stock | 2.57K | $870K | $338.25 | Apr 4, 2025 | Deferred Fee Plan |
PRUDENTIAL FINANCIAL INC | Director | Notional Shares - Optional | 3.93K | $413K | $105.04 | Mar 13, 2025 | Direct |
NEUROCRINE BIOSCIENCES INC | Director | Non-Qualified Stock Option | 2.98K | $219K | $73.60 | May 22, 2024 | Direct |
NEUROCRINE BIOSCIENCES INC | Director | Restricted Stock Unit | 1.44K | $204K | $141.90 | May 22, 2024 | Direct |
PRUDENTIAL FINANCIAL INC | Director | 2024 Restricted Stock Units | 1.32K | $139K | $105.04 | Mar 13, 2025 | Direct |
PRUDENTIAL FINANCIAL INC | Director | 2023 Restricted Stock Units | 0 | $0 | $116.58 | May 9, 2024 | Direct |
REGENERON PHARMACEUTICALS, INC. | Director | Non-Qualified Stock Option (right to buy) | 1.96K | Jan 2, 2025 | Direct |